Prevalence of doravirine cross-resistance in HIV-infected adults who failed first-line ART in China, 2014–18

Abstract

In China, the prevalence of doravirine cross-resistance among patients who have failed first-line ART is high. Therefore, doravirine should not be used blindly without genotypic resistance testing and is not recommended for people who have failed first-line NNRTI-based ART.